SRAX INC (SRAX) Fundamental Analysis & Valuation

NASDAQ:SRAX • US78472M1062

Current stock price

0.6 USD
-0.98 (-62.03%)
At close:
0.62 USD
+0.02 (+3.33%)
After Hours:

This SRAX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. SRAX Profitability Analysis

1.1 Basic Checks

  • SRAX had negative earnings in the past year.
  • In the past year SRAX has reported a negative cash flow from operations.
SRAX Yearly Net Income VS EBIT VS OCF VS FCFSRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 -10M -20M -30M

1.2 Ratios

  • SRAX has negative profitability rations, so we won't be analyzing them here.
  • With a decent Return On Invested Capital value of 0.04%, SRAX is doing good in the industry, outperforming 73.06% of the companies in the same industry.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC 0.04%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRAX Yearly ROA, ROE, ROICSRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 50 -50 -100 -150 -200

1.3 Margins

  • The Operating Margin of SRAX (0.05%) is better than 73.06% of its industry peers.
  • SRAX has a Gross Margin of 73.34%. This is in the better half of the industry: SRAX outperforms 70.03% of its industry peers.
  • In the last couple of years the Gross Margin of SRAX has grown nicely.
Industry RankSector Rank
OM 0.05%
PM (TTM) N/A
GM 73.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.58%
GM growth 5Y16.6%
SRAX Yearly Profit, Operating, Gross MarginsSRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. SRAX Health Analysis

2.1 Basic Checks

  • SRAX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, SRAX has more shares outstanding
  • Compared to 1 year ago, SRAX has an improved debt to assets ratio.
SRAX Yearly Shares OutstandingSRAX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M
SRAX Yearly Total Debt VS Total AssetsSRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

2.2 Solvency

  • SRAX has an Altman-Z score of 0.23. This is a bad value and indicates that SRAX is not financially healthy and even has some risk of bankruptcy.
  • SRAX's Altman-Z score of 0.23 is on the low side compared to the rest of the industry. SRAX is outperformed by 67.00% of its industry peers.
  • There is no outstanding debt for SRAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.23
ROIC/WACC0
WACC10.1%
SRAX Yearly LT Debt VS Equity VS FCFSRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 10M -10M 20M -20M

2.3 Liquidity

  • SRAX has a Current Ratio of 1.13. This is a normal value and indicates that SRAX is financially healthy and should not expect problems in meeting its short term obligations.
  • SRAX's Current ratio of 1.13 is on the low side compared to the rest of the industry. SRAX is outperformed by 71.72% of its industry peers.
  • SRAX has a Quick Ratio of 1.13. This is a normal value and indicates that SRAX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of SRAX (1.13) is worse than 71.04% of its industry peers.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 1.13
SRAX Yearly Current Assets VS Current LiabilitesSRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. SRAX Growth Analysis

3.1 Past

  • SRAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.18%, which is quite impressive.
  • The Revenue has grown by 109.34% in the past year. This is a very strong growth!
  • SRAX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.67% yearly.
EPS 1Y (TTM)42.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%123.2%
Revenue 1Y (TTM)109.34%
Revenue growth 3Y39.3%
Revenue growth 5Y-5.67%
Sales Q2Q%37.85%

3.2 Future

  • SRAX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 50.52% yearly.
  • SRAX is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.17% yearly.
EPS Next Y124.58%
EPS Next 2Y50.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-7.07%
Revenue Next 2Y-5.17%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SRAX Yearly Revenue VS EstimatesSRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
SRAX Yearly EPS VS EstimatesSRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

4

4. SRAX Valuation Analysis

4.1 Price/Earnings Ratio

  • SRAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 1.95, which indicates a rather cheap valuation of SRAX.
  • 100.00% of the companies in the same industry are more expensive than SRAX, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, SRAX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 1.95
SRAX Price Earnings VS Forward Price EarningsSRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -65.27
SRAX Per share dataSRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as SRAX's earnings are expected to grow with 50.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.52%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SRAX Dividend Analysis

5.1 Amount

  • No dividends for SRAX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SRAX Fundamentals: All Metrics, Ratios and Statistics

SRAX INC

NASDAQ:SRAX (3/8/2023, 8:07:58 PM)

After market: 0.62 +0.02 (+3.33%)

0.6

-0.98 (-62.03%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)02-02
Earnings (Next)04-03
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners9.92%
Ins Owner Change0%
Market Cap15.79M
Revenue(TTM)28.76M
Net Income(TTM)-19.94M
Analysts84.44
Price Target6.73 (1021.67%)
Short Float %0.63%
Short Ratio0.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-107.64%
Min EPS beat(2)-107.64%
Max EPS beat(2)-107.64%
EPS beat(4)0
Avg EPS beat(4)-1488.54%
Min EPS beat(4)-3627.65%
Max EPS beat(4)-107.64%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-35.89%
Min Revenue beat(2)-49.18%
Max Revenue beat(2)-22.6%
Revenue beat(4)1
Avg Revenue beat(4)-15.97%
Min Revenue beat(4)-49.18%
Max Revenue beat(4)9.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-24.72%
EPS NQ rev (1m)47.14%
EPS NQ rev (3m)-130.83%
EPS NY rev (1m)-20.14%
EPS NY rev (3m)-20.14%
Revenue NQ rev (1m)-19.15%
Revenue NQ rev (3m)-19.15%
Revenue NY rev (1m)-40.35%
Revenue NY rev (3m)-40.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.95
P/S 0.55
P/FCF N/A
P/OCF N/A
P/B 0.64
P/tB 2.97
EV/EBITDA -65.27
EPS(TTM)-1.16
EYN/A
EPS(NY)0.31
Fwd EY51.34%
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS1.09
BVpS0.94
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC 0.04%
ROICexc N/A
ROICexgc N/A
OM 0.05%
PM (TTM) N/A
GM 73.34%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.58%
GM growth 5Y16.6%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 1.6
Cap/Depr 127.87%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.13
Quick Ratio 1.13
Altman-Z 0.23
F-Score4
WACC10.1%
ROIC/WACC0
Cap/Depr(3y)101.84%
Cap/Depr(5y)118.99%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%123.2%
EPS Next Y124.58%
EPS Next 2Y50.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)109.34%
Revenue growth 3Y39.3%
Revenue growth 5Y-5.67%
Sales Q2Q%37.85%
Revenue Next Year-7.07%
Revenue Next 2Y-5.17%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y100.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year322.13%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.54%
OCF growth 3YN/A
OCF growth 5YN/A

SRAX INC / SRAX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SRAX INC (SRAX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRAX.


Can you provide the valuation status for SRAX INC?

ChartMill assigns a valuation rating of 7 / 10 to SRAX INC (SRAX). This can be considered as Undervalued.


What is the profitability of SRAX stock?

SRAX INC (SRAX) has a profitability rating of 1 / 10.


What is the financial health of SRAX INC (SRAX) stock?

The financial health rating of SRAX INC (SRAX) is 2 / 10.